Patient-reported outcomes in high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
出版年份 2023 全文链接
标题
Patient-reported outcomes in high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages 113420
出版商
Elsevier BV
发表日期
2023-11-05
DOI
10.1016/j.ejca.2023.113420
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study
- (2022) Massimo Cristofanilli et al. CLINICAL CANCER RESEARCH
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
- (2021) D.J. Slamon et al. ANNALS OF ONCOLOGY
- Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy
- (2021) Antonio Di Meglio et al. CURRENT OPINION IN ONCOLOGY
- Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
- (2021) Stephen Johnston et al. npj Breast Cancer
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
- (2021) Yen-Shen Lu et al. CLINICAL CANCER RESEARCH
- Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
- (2021) Zsuzsanna Kahan et al. EUROPEAN JOURNAL OF CANCER
- International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium
- (2020) Corneel Coens et al. LANCET ONCOLOGY
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
- (2019) H. S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors
- (2019) K. M. de Ligt et al. BREAST CANCER RESEARCH AND TREATMENT
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research
- (2019) Johannes M. Giesinger et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
- (2018) H S Rugo et al. ANNALS OF ONCOLOGY
- Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
- (2018) Sunil Verma et al. BREAST CANCER RESEARCH AND TREATMENT
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
- (2016) N. Harbeck et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications
- (2016) Stefan Stefanovic et al. SUPPORTIVE CARE IN CANCER
- Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2012) K. Cocks et al. EUROPEAN JOURNAL OF CANCER
- Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials
- (2008) Kim Cocks et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now